Literature DB >> 25229278

Streptococcal acute pharyngitis.

Lais Martins Moreira Anjos1, Mariana Barros Marcondes1, Mariana Ferreira Lima1, Alessandro Lia Mondelli1, Marina Politi Okoshi1.   

Abstract

Acute pharyngitis/tonsillitis, which is characterized by inflammation of the posterior pharynx and tonsils, is a common disease. Several viruses and bacteria can cause acute pharyngitis; however, Streptococcus pyogenes (also known as Lancefield group A β-hemolytic streptococci) is the only agent that requires an etiologic diagnosis and specific treatment. S. pyogenes is of major clinical importance because it can trigger post-infection systemic complications, acute rheumatic fever, and post-streptococcal glomerulonephritis. Symptom onset in streptococcal infection is usually abrupt and includes intense sore throat, fever, chills, malaise, headache, tender enlarged anterior cervical lymph nodes, and pharyngeal or tonsillar exudate. Cough, coryza, conjunctivitis, and diarrhea are uncommon, and their presence suggests a viral cause. A diagnosis of pharyngitis is supported by the patient's history and by the physical examination. Throat culture is the gold standard for diagnosing streptococcus pharyngitis. However, it has been underused in public health services because of its low availability and because of the 1- to 2-day delay in obtaining results. Rapid antigen detection tests have been used to detect S. pyogenes directly from throat swabs within minutes. Clinical scoring systems have been developed to predict the risk of S. pyogenes infection. The most commonly used scoring system is the modified Centor score. Acute S. pyogenes pharyngitis is often a self-limiting disease. Penicillins are the first-choice treatment. For patients with penicillin allergy, cephalosporins can be an acceptable alternative, although primary hypersensitivity to cephalosporins can occur. Another drug option is the macrolides. Future perspectives to prevent streptococcal pharyngitis and post-infection systemic complications include the development of an anti-Streptococcus pyogenes vaccine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25229278     DOI: 10.1590/0037-8682-0265-2013

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  6 in total

Review 1.  Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.

Authors:  Ze-Liang Wu; Jun Zhao; Rong Xu
Journal:  Int J Nanomedicine       Date:  2020-12-01

2.  Appropriateness of diagnosis of streptococcal pharyngitis among Thai community pharmacists according to the Centor criteria.

Authors:  Woranuch Saengcharoen; Pornchanok Jaisawang; Palita Udomcharoensab; Kittika Buathong; Sanguan Lerkiatbundit
Journal:  Int J Clin Pharm       Date:  2016-08-29

3.  Evaluation of Rational Drug Use for Acute Pharyngitis Associated with the Incidence and Prevalence of the Disease at Two Community Health Centers in Indonesia.

Authors:  Cindra T Yuniar; Kusnandar Anggadiredja; Alfi N Islamiyah
Journal:  Sci Pharm       Date:  2017-04-28

4.  Valuing tonsillitis manifestations in schoolchildren in Rio de Janeiro.

Authors:  Rafaela Valentim Goldenzon; Tiago Oliveira Lucas; Maria de Marilacc Lima Roiseman; Marta Cristine Félix Rodrigues; Adriana Rodrigues Fonseca; Sheila Knupp Feitosa de Oliveira; Andréa Valentim Goldenzon
Journal:  Einstein (Sao Paulo)       Date:  2022-03-14

5.  Diagnostic Accuracy of Centor Score for Diagnosis of Group A Streptococcal Pharyngitis among Adults in Primary Care Clinics in Malaysia.

Authors:  AbdulRahman Muthanna; Nurainul Hana Shamsuddin; Aneesa Abdul Rashid; Sazlina Shariff Ghazali; Rukman Awang Hamat; Maliza Mawardi; Hani Syahida Salim; Siti Zulaikha Zakariah
Journal:  Malays J Med Sci       Date:  2022-08-29

Review 6.  Alterations in the Nervous System and Gut Microbiota after β-Hemolytic Streptococcus Group A Infection-Characteristics and Diagnostic Criteria of PANDAS Recognition.

Authors:  Jacek Baj; Elżbieta Sitarz; Alicja Forma; Katarzyna Wróblewska; Hanna Karakuła-Juchnowicz
Journal:  Int J Mol Sci       Date:  2020-02-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.